Cerebral Protection - MD Anaesthesia Examination Answer

DEFINITION

• Its high metabolic rate (CMRO2 ~3.5 mL O2/100 g/min; constitutes 20% of total body O2 consumption)
• Inability to store substrate (no significant glycogen; glucose for only ~2 minutes of function)
• Inability to rapidly dispose of toxic metabolites
• Tight anatomical confinement within the skull

PATHOPHYSIOLOGY OF CEREBRAL ISCHEMIA (the basis for protection strategies)

1. Failure of ATP-dependent Na+/K+ pump -> membrane depolarization
2. Massive intracellular Ca2+ influx via NMDA receptors (triggered by glutamate excitotoxicity)
3. Activation of lipases and proteases -> structural neuronal damage
4. Free fatty acid accumulation -> prostaglandins and leukotrienes (mediators of injury)
5. Lactic acidosis from anaerobic glycolysis (worsened by hyperglycemia)
6. Reperfusion injury - paradoxical worsening on restoration of flow due to free radical burst

• Global ischemia - cardiac arrest, severe hypotension, severe anaemia
• Focal ischemia - embolism, arterial disruption; surrounded by an ischemic penumbra (viable tissue with marginal perfusion <15 mL/100 g/min that is potentially salvageable)

WAYS OF ACHIEVING CEREBRAL PROTECTION

I. GENERAL PHYSIOLOGICAL MEASURES

1. Maintenance of Adequate Cerebral Perfusion Pressure (CPP)

• CPP = MAP - ICP (or CVP, whichever is higher)
• Normal CPP: 60-80 mmHg
• Avoid hypotension; maintain MAP within the autoregulatory range (MAP 60-160 mmHg in normotenives)
• In focal ischemia, augmenting CPP helps sustain the penumbra via collateral circulation

2. Optimisation of Oxygen Delivery

• Maintain adequate haemoglobin (avoid severe anaemia)
• Maintain normal arterial PaO2; avoid hypoxia
• Avoid hyperoxia (may increase free radical generation)

3. Normocarbia

• PaCO2 directly affects CBF (CBF changes ~2-3% per 1 mmHg change in PaCO2)
• Hypocapnia: cerebral vasoconstriction -> may aggravate focal ischemia ("steal" phenomenon is not favored; direct ischemia is the risk)
• Hypercapnia: vasodilation -> worsens intracellular acidosis; cerebrovascular steal with focal ischemia
• Target: PaCO2 35-40 mmHg (normocarbia)

4. Glucose Control

• Hyperglycemia (>180 mg/dL) worsens outcome in ischemia - excess glucose is converted to lactate anaerobically, worsening cerebral acidosis
• Hypoglycemia is equally harmful - glucose is the brain's sole aerobic substrate
• Target blood glucose: <180 mg/dL (some advocate tighter control 140-180 mg/dL)

5. Avoidance of Hyperthermia

• Even mild hyperthermia (>37.5°C) increases CMRO2 and exacerbates ischemia
• Actively prevent pyrexia in all at-risk patients

6. Control of Intracranial Pressure (ICP)

• Elevated ICP reduces CPP
• Measures: head-up 30°, normoventilation, mannitol, hypertonic saline, CSF drainage, avoid venous outflow obstruction

II. HYPOTHERMIA

• Reduces CMRO2 by approximately 5-7% per 1°C fall in temperature
• Unlike anaesthetic agents, hypothermia reduces both electrical (functional) and basal (homeostatic) metabolic requirements
• Anaesthetics can only produce isoelectric EEG reducing CMRO2 by ~60%; hypothermia can reduce even the basal oxygen requirement essential for neuronal survival
• Decreases glutamate release and excitotoxicity
• Reduces free radical production and inflammatory mediators
• Even a 1°C decrease shows protective effects in animal models, suggesting mechanisms beyond metabolic reduction alone

• DHCA provides up to ~60 minutes of safe circulatory arrest time at 12-18°C
• Post-cardiac arrest: cooling to 32-34°C for 12-24 hours - earlier data supported neurologic benefit; more recent studies show less consistent benefit but it remains used selectively
• Neonates with hypoxic-ischemic encephalopathy (HIE): cooling for 72 hours consistently improves outcomes

III. PHARMACOLOGICAL AGENTS

A. Anaesthetic Agents

• Reduce CMRO2 by producing burst suppression or isoelectric EEG (up to 60% reduction in electrical activity)
• Reduce ICP
• Proven benefit in focal ischemia in animal models
• Used clinically as a cerebral protectant before planned temporary vessel occlusion (e.g., temporary clipping during aneurysm surgery) and in DHCA protocols
• Limitation: no effect on basal metabolic requirements; cardiovascular depression; long half-life

• Reduces CMRO2 and ICP; produces burst suppression at high doses
• Common protocol for temporary clipping: propofol 1-2 mg/kg bolus followed by infusion at 150 mcg/kg/min titrated to burst suppression on EEG
• Reasonable alternative to barbiturates

• Reduces CMRO2; produces burst suppression
• Less cardiovascular depression than barbiturates
• Adrenocortical suppression limits prolonged use

• Produce burst suppression at high doses (>1.2-1.5 MAC)
• May reduce ischemia-induced glutamate release
• Activate ATP-dependent K+ channels
• Augment CBF
• Effects are non-uniform across the brain (limitation)

• Blocks glutamate at NMDA receptors - theoretical neuroprotective mechanism
• Historically avoided in neuro patients due to ICP concern; this concern appears unfounded in mechanically ventilated patients
• Clinical use for neuroprotection remains limited; more RCT data needed

• NMDA receptor antagonist; also activates K+ channels
• Suggested neuroprotective properties; not widely available

B. Non-Anaesthetic Pharmacological Agents

• Nimodipine: used for cerebral vasospasm after subarachnoid haemorrhage (reduces vasospasm-related ischemia)
• General calcium channel blockers have not proven clinically useful as cerebral protectants

• Methylprednisolone (30 mg/kg) or dexamethasone given before DHCA in some protocols
• Reduce cerebral oedema; useful in brain tumour-related oedema
• NOT proven to improve outcome after global or focal ischemia generally

• NMDA receptor antagonist; blocks voltage-gated channels
• Antenatal magnesium reduces cerebral palsy risk in premature infants
• Adult clinical neuroprotection trials have been disappointing

• Osmotic agent; reduces cerebral oedema and ICP
• Used peri-operatively as part of cerebral protection protocols (0.5 g/kg in DHCA)

• Agents like edaravone; under investigation
• No definitive human clinical trial success

• Activates antiapoptotic pathways; reduces inflammation
• Promising in preclinical studies; clinical data still incomplete

• Upregulate nitric oxide synthase; anti-inflammatory and antioxidant effects
• Under investigation for neuroprotection

• Membrane stabiliser; some preclinical neuroprotection data
• Used perioperatively (IV/intratracheal) to suppress cough/straining (ICP spikes) during emergence

IV. SURGICAL AND PROCEDURAL MEASURES

• De-airing of cardiac chambers before ejection
• Filling the surgical field with CO2 (rapidly reabsorbed if embolised)
• Epiaortic echocardiography (most sensitive for atheromatous plaque - most specific technique for guiding aortic cannulation site)
• TEE to detect intracardiac air
• Minimising aortic manipulation, clamping episodes, and graft sites
• Sutureless proximal anastomotic devices

• Head-down (Trendelenburg) during intracardiac air evacuation - reduces cerebral gas emboli
• Ice packing around the head during DHCA - delays external rewarming and aids brain cooling
• Eyes protected during ice packing

• Rapid rewarming creates arterio-venous temperature gradients -> gas bubble formation in blood
• An excessive heat exchanger-to-patient temperature gradient causes brain hyperthermia -> ischemia
• Rewarming should be gradual; avoid core temperature >37°C

V. MONITORING TO GUIDE CEREBRAL PROTECTION

• EEG / Processed EEG (BIS): titration of anaesthetic depth; confirm burst suppression or isoelectric state during ischemia
• Cerebral Oximetry (NIRS / rSO2): near-infrared spectroscopy; detects regional frontal cortical hypoxia; allows intervention (increase MAP, Hb, FiO2, or PaCO2)
• Transcranial Doppler (TCD): detects microemboli; assesses CBF velocity
• Evoked Potentials (SSEP, MEP, BAER): detect functional ischemia intraoperatively
• Jugular venous oxygen saturation (SjvO2): reflects global cerebral O2 extraction (normal 54-75%)
• Brain tissue PO2 (PbtO2): direct focal tissue oxygenation monitoring in the ICU setting

SUMMARY TABLE

KEY EXAM POINTS

1. Prevention is the most effective cerebral protection - once injury occurs, all measures are attenuating, not reversing.
2. Hypothermia reduces both basal and electrical CMRO2; anaesthetics only reduce electrical (functional) CMRO2.
3. No single pharmacological agent has shown definitive neuroprotection in large human RCTs.
4. Propofol/barbiturate burst suppression before planned temporary focal ischemia (e.g., aneurysm clipping) is the most common pharmacological strategy in practice.
5. Hyperglycemia (>180 mg/dL) worsens outcome - worsens lactic acidosis in ischaemic tissue.
6. Mild hyperthermia is harmful - actively maintain normothermia.
7. DHCA at 12-18°C permits up to ~60 minutes safe circulatory arrest.
8. Epiaortic echocardiography is the most sensitive/specific technique for detecting aortic atheromatous plaque during cardiac surgery.